Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents
(2013) In Bioorganic & Medicinal Chemistry Letters 23(4). p.934-938- Abstract
Based on known heterocyclic topoisomerase II inhibitors and anticancer agents, various indenoindolone derivatives were predicted as potential topoisomerase II-inhibiting anticancer agents. They are hydrazones, (thio)semicarbazones, and oximes of indenoindolones, and indenoindolols. These derivatives with suitable substitutions exhibited potent specific inhibition of human DNA TopoIIα while not showing inhibition of topoisomerase I and DNA intercalation, despite the fact that parent indenoindolones are known poor/moderate inhibitors of topoisomerase II. The potent topoisomerase II inhibitor indenoindolone derivatives exhibited good anticancer activities compared to etoposide and 5-fluorouracil, and relatively low toxicity to normal... (More)
Based on known heterocyclic topoisomerase II inhibitors and anticancer agents, various indenoindolone derivatives were predicted as potential topoisomerase II-inhibiting anticancer agents. They are hydrazones, (thio)semicarbazones, and oximes of indenoindolones, and indenoindolols. These derivatives with suitable substitutions exhibited potent specific inhibition of human DNA TopoIIα while not showing inhibition of topoisomerase I and DNA intercalation, despite the fact that parent indenoindolones are known poor/moderate inhibitors of topoisomerase II. The potent topoisomerase II inhibitor indenoindolone derivatives exhibited good anticancer activities compared to etoposide and 5-fluorouracil, and relatively low toxicity to normal cells. These derivatizations of indenoindolones were found to result in enhancement of anticancer activities.
(Less)
- author
- publishing date
- 2013-02-15
- type
- Contribution to journal
- publication status
- published
- keywords
- Antineoplastic Agents/chemistry, DNA Topoisomerases, Type II/chemistry, Humans, Indoles/chemistry, Models, Molecular, Neoplasms/drug therapy, Topoisomerase II Inhibitors/chemistry
- in
- Bioorganic & Medicinal Chemistry Letters
- volume
- 23
- issue
- 4
- pages
- 934 - 938
- publisher
- Elsevier
- external identifiers
-
- scopus:84872939428
- pmid:23321564
- ISSN
- 0960-894X
- DOI
- 10.1016/j.bmcl.2012.12.063
- language
- English
- LU publication?
- no
- additional info
- Copyright © 2012 Elsevier Ltd. All rights reserved.
- id
- 83e5fe3c-1436-4200-ac26-6b545c2bf07d
- date added to LUP
- 2025-01-30 10:31:09
- date last changed
- 2025-06-06 13:53:22
@article{83e5fe3c-1436-4200-ac26-6b545c2bf07d, abstract = {{<p>Based on known heterocyclic topoisomerase II inhibitors and anticancer agents, various indenoindolone derivatives were predicted as potential topoisomerase II-inhibiting anticancer agents. They are hydrazones, (thio)semicarbazones, and oximes of indenoindolones, and indenoindolols. These derivatives with suitable substitutions exhibited potent specific inhibition of human DNA TopoIIα while not showing inhibition of topoisomerase I and DNA intercalation, despite the fact that parent indenoindolones are known poor/moderate inhibitors of topoisomerase II. The potent topoisomerase II inhibitor indenoindolone derivatives exhibited good anticancer activities compared to etoposide and 5-fluorouracil, and relatively low toxicity to normal cells. These derivatizations of indenoindolones were found to result in enhancement of anticancer activities.</p>}}, author = {{Kashyap, Maneesh and Kandekar, Somnath and Baviskar, Ashish T and Das, Dipon and Preet, Ranjan and Mohapatra, Purusottam and Satapathy, Shakti Ranjan and Siddharth, Sumit and Guchhait, Sankar K and Kundu, Chanakya N and Banerjee, Uttam C}}, issn = {{0960-894X}}, keywords = {{Antineoplastic Agents/chemistry; DNA Topoisomerases, Type II/chemistry; Humans; Indoles/chemistry; Models, Molecular; Neoplasms/drug therapy; Topoisomerase II Inhibitors/chemistry}}, language = {{eng}}, month = {{02}}, number = {{4}}, pages = {{934--938}}, publisher = {{Elsevier}}, series = {{Bioorganic & Medicinal Chemistry Letters}}, title = {{Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents}}, url = {{http://dx.doi.org/10.1016/j.bmcl.2012.12.063}}, doi = {{10.1016/j.bmcl.2012.12.063}}, volume = {{23}}, year = {{2013}}, }